66 related articles for article (PubMed ID: 38454481)
1. Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström LS; Tobin NP
Breast Cancer Res; 2024 Mar; 26(1):38. PubMed ID: 38454481
[TBL] [Abstract][Full Text] [Related]
2. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
Prat A; Parker JS; Fan C; Cheang MCU; Miller LD; Bergh J; Chia SKL; Bernard PS; Nielsen TO; Ellis MJ; Carey LA; Perou CM
Ann Oncol; 2012 Nov; 23(11):2866-2873. PubMed ID: 22532584
[TBL] [Abstract][Full Text] [Related]
3. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Vallon-Christersson J; Häkkinen J; Hegardt C; Saal LH; Larsson C; Ehinger A; Lindman H; Olofsson H; Sjöblom T; Wärnberg F; Ryden L; Loman N; Malmberg M; Borg Å; Staaf J
Sci Rep; 2019 Aug; 9(1):12184. PubMed ID: 31434940
[TBL] [Abstract][Full Text] [Related]
4. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
5. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
[No Abstract] [Full Text] [Related]
6. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Cockburn JG; Hallett RM; Gillgrass AE; Dias KN; Whelan T; Levine MN; Hassell JA; Bane A
BMC Cancer; 2016 Jul; 16():555. PubMed ID: 27469239
[TBL] [Abstract][Full Text] [Related]
7. Anticancer drugs are not well tolerated in all older patients with cancer.
Wildiers H; de Glas NA
Lancet Healthy Longev; 2020 Oct; 1(1):e43-e47. PubMed ID: 36094187
[TBL] [Abstract][Full Text] [Related]
8. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.
Noordhoek I; Bastiaannet E; de Glas NA; Scheepens J; Esserman LJ; Wesseling J; Scholten AN; Schröder CP; Elias SG; Kroep JR; Portielje JEA; Kleijn M; Liefers GJ
J Geriatr Oncol; 2022 Nov; 13(8):1172-1177. PubMed ID: 35871138
[TBL] [Abstract][Full Text] [Related]
9. Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study.
Kjällquist U; Acs B; Margolin S; Karlsson E; Kessler LE; Garcia Hernandez S; Ekholm M; Lundgren C; Olsson E; Lindman H; Foukakis T; Matikas A; Hartman J
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681597
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM; Litvak A; Mayer EL; Pusztai L; Raab R; Wolff AC; Stearns V
J Clin Oncol; 2022 Jun; 40(16):1816-1837. PubMed ID: 35439025
[TBL] [Abstract][Full Text] [Related]
11. The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.
Iles K; Roberson ML; Spanheimer P; Gallagher K; Ollila DW; Strassle PD; Downs-Canner S
NPJ Breast Cancer; 2022 Mar; 8(1):27. PubMed ID: 35232996
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A; Yu NY; Iftimi A; Tobin NP; van 't Veer L; Nordenskjöld B; Benz CC; Fornander T; Perez-Tenorio G; Stål O; Esserman LJ; Yau C; Lindström LS
Int J Cancer; 2022 Jun; 150(12):2072-2082. PubMed ID: 35179782
[TBL] [Abstract][Full Text] [Related]
13. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL; Dhesy-Thind S; Rastogi P; Alba E; Delaloge S; Martin M; Kelly CM; Ruiz-Borrego M; Gil-Gil M; Arce-Salinas CH; Brain EGC; Lee ES; Pierga JY; Bermejo B; Ramos-Vazquez M; Jung KH; Ferrero JM; Schott AF; Shak S; Sharma P; Lew DL; Miao J; Tripathy D; Pusztai L; Hortobagyi GN
N Engl J Med; 2021 Dec; 385(25):2336-2347. PubMed ID: 34914339
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
